ArticleInternational journal of molecular sciences2024
Blood Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Promising Screening Biomarkers for Brain Metastases in Patients with Lung Cancer.
Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Increased Blood Levels of NfL, GFAP, and Placental Growth Factor After Radiotherapy to the Brain.Annals of clinical and translational neurology · 2026Article
- Neurofilament light and glial fibrillary acidic protein do not reflect neuronal or glial damage during different intracranial radiotherapy regimes: a pilot study.Frontiers in oncology · 2026Article
- Brain metastasis from non-small cell lung cancer: crosstalk between cancer cells and tumor microenvironment components.Experimental & molecular medicine · 2025Review
- Associations Between Malignant Tumors and Alzheimer's Disease: A Cross-Sectional Study.Brain and behavior · 2025Article
- Molecular minimal residual disease in resected non-small cell lung cancer: "flattening the curve".Translational lung cancer research · 2025Article
- Evaluating liquid biopsy biomarkers for early detection of brain metastasis: A systematic review.Neuro-oncology practice · 2025Article
- Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The diagnosis of brain metastases (BMs) in patients with lung cancer (LC) predominantly relies on magnetic resonance imaging (MRI), a method that is constrained by high costs and limited accessibility. This study explores the potential of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) as screening biomarkers for BMs in LC patients. We conducted a retrospective analysis of 700 LC cases at the National Cancer Center, Korea, from July 2020 to June 2022, measuring sNfL and sGFAP levels at initial LC diagnosis. The likelihood of BM was evaluated using multivariate analysis and a predictive nomogram. Additionally, we prospectively monitored 177 samples from 46 LC patients initially without BM. Patients with BMs (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.